IBDEI2T8 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,44821,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
;;^UTILITY(U,$J,358.3,44821,1,4,0)
;;=4^L49.1
;;^UTILITY(U,$J,358.3,44821,2)
;;=^5009191
;;^UTILITY(U,$J,358.3,44822,0)
;;=L49.2^^170^2237^18
;;^UTILITY(U,$J,358.3,44822,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44822,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
;;^UTILITY(U,$J,358.3,44822,1,4,0)
;;=4^L49.2
;;^UTILITY(U,$J,358.3,44822,2)
;;=^5009192
;;^UTILITY(U,$J,358.3,44823,0)
;;=L49.3^^170^2237^19
;;^UTILITY(U,$J,358.3,44823,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44823,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 30-39% Body Surface
;;^UTILITY(U,$J,358.3,44823,1,4,0)
;;=4^L49.3
;;^UTILITY(U,$J,358.3,44823,2)
;;=^5009193
;;^UTILITY(U,$J,358.3,44824,0)
;;=L49.4^^170^2237^20
;;^UTILITY(U,$J,358.3,44824,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44824,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 40-49% Body Surface
;;^UTILITY(U,$J,358.3,44824,1,4,0)
;;=4^L49.4
;;^UTILITY(U,$J,358.3,44824,2)
;;=^5009194
;;^UTILITY(U,$J,358.3,44825,0)
;;=L49.5^^170^2237^21
;;^UTILITY(U,$J,358.3,44825,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44825,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 50-59% Body Surface
;;^UTILITY(U,$J,358.3,44825,1,4,0)
;;=4^L49.5
;;^UTILITY(U,$J,358.3,44825,2)
;;=^5009195
;;^UTILITY(U,$J,358.3,44826,0)
;;=L49.6^^170^2237^22
;;^UTILITY(U,$J,358.3,44826,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44826,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 60-69% Body Surface
;;^UTILITY(U,$J,358.3,44826,1,4,0)
;;=4^L49.6
;;^UTILITY(U,$J,358.3,44826,2)
;;=^5009196
;;^UTILITY(U,$J,358.3,44827,0)
;;=L49.7^^170^2237^23
;;^UTILITY(U,$J,358.3,44827,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44827,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 70-79% Body Surface
;;^UTILITY(U,$J,358.3,44827,1,4,0)
;;=4^L49.7
;;^UTILITY(U,$J,358.3,44827,2)
;;=^5009197
;;^UTILITY(U,$J,358.3,44828,0)
;;=L49.8^^170^2237^24
;;^UTILITY(U,$J,358.3,44828,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44828,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 80-89% Body Surface
;;^UTILITY(U,$J,358.3,44828,1,4,0)
;;=4^L49.8
;;^UTILITY(U,$J,358.3,44828,2)
;;=^5009198
;;^UTILITY(U,$J,358.3,44829,0)
;;=L49.9^^170^2237^27
;;^UTILITY(U,$J,358.3,44829,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44829,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ > 89% Body Surface
;;^UTILITY(U,$J,358.3,44829,1,4,0)
;;=4^L49.9
;;^UTILITY(U,$J,358.3,44829,2)
;;=^5009199
;;^UTILITY(U,$J,358.3,44830,0)
;;=Z65.5^^170^2237^28
;;^UTILITY(U,$J,358.3,44830,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44830,1,3,0)
;;=3^Exposure to Disaster/War/Hostilities
;;^UTILITY(U,$J,358.3,44830,1,4,0)
;;=4^Z65.5
;;^UTILITY(U,$J,358.3,44830,2)
;;=^5063184
;;^UTILITY(U,$J,358.3,44831,0)
;;=Z77.22^^170^2237^29
;;^UTILITY(U,$J,358.3,44831,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44831,1,3,0)
;;=3^Exposure to/Contact w/ Environmental Tobacco Smoke
;;^UTILITY(U,$J,358.3,44831,1,4,0)
;;=4^Z77.22
;;^UTILITY(U,$J,358.3,44831,2)
;;=^5063324
;;^UTILITY(U,$J,358.3,44832,0)
;;=L30.9^^170^2237^5
;;^UTILITY(U,$J,358.3,44832,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44832,1,3,0)
;;=3^Eczema,Unspec
;;^UTILITY(U,$J,358.3,44832,1,4,0)
;;=4^L30.9
;;^UTILITY(U,$J,358.3,44832,2)
;;=^5009159
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2T8 3784 printed Apr 09, 2024@21:14:38 Page 2
IBDEI2T8 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,44821,1,3,0)
+2 ;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
+3 ;;^UTILITY(U,$J,358.3,44821,1,4,0)
+4 ;;=4^L49.1
+5 ;;^UTILITY(U,$J,358.3,44821,2)
+6 ;;=^5009191
+7 ;;^UTILITY(U,$J,358.3,44822,0)
+8 ;;=L49.2^^170^2237^18
+9 ;;^UTILITY(U,$J,358.3,44822,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,44822,1,3,0)
+12 ;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
+13 ;;^UTILITY(U,$J,358.3,44822,1,4,0)
+14 ;;=4^L49.2
+15 ;;^UTILITY(U,$J,358.3,44822,2)
+16 ;;=^5009192
+17 ;;^UTILITY(U,$J,358.3,44823,0)
+18 ;;=L49.3^^170^2237^19
+19 ;;^UTILITY(U,$J,358.3,44823,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,44823,1,3,0)
+22 ;;=3^Exfoliation d/t Erythematous Cond w/ 30-39% Body Surface
+23 ;;^UTILITY(U,$J,358.3,44823,1,4,0)
+24 ;;=4^L49.3
+25 ;;^UTILITY(U,$J,358.3,44823,2)
+26 ;;=^5009193
+27 ;;^UTILITY(U,$J,358.3,44824,0)
+28 ;;=L49.4^^170^2237^20
+29 ;;^UTILITY(U,$J,358.3,44824,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,44824,1,3,0)
+32 ;;=3^Exfoliation d/t Erythematous Cond w/ 40-49% Body Surface
+33 ;;^UTILITY(U,$J,358.3,44824,1,4,0)
+34 ;;=4^L49.4
+35 ;;^UTILITY(U,$J,358.3,44824,2)
+36 ;;=^5009194
+37 ;;^UTILITY(U,$J,358.3,44825,0)
+38 ;;=L49.5^^170^2237^21
+39 ;;^UTILITY(U,$J,358.3,44825,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,44825,1,3,0)
+42 ;;=3^Exfoliation d/t Erythematous Cond w/ 50-59% Body Surface
+43 ;;^UTILITY(U,$J,358.3,44825,1,4,0)
+44 ;;=4^L49.5
+45 ;;^UTILITY(U,$J,358.3,44825,2)
+46 ;;=^5009195
+47 ;;^UTILITY(U,$J,358.3,44826,0)
+48 ;;=L49.6^^170^2237^22
+49 ;;^UTILITY(U,$J,358.3,44826,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,44826,1,3,0)
+52 ;;=3^Exfoliation d/t Erythematous Cond w/ 60-69% Body Surface
+53 ;;^UTILITY(U,$J,358.3,44826,1,4,0)
+54 ;;=4^L49.6
+55 ;;^UTILITY(U,$J,358.3,44826,2)
+56 ;;=^5009196
+57 ;;^UTILITY(U,$J,358.3,44827,0)
+58 ;;=L49.7^^170^2237^23
+59 ;;^UTILITY(U,$J,358.3,44827,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,44827,1,3,0)
+62 ;;=3^Exfoliation d/t Erythematous Cond w/ 70-79% Body Surface
+63 ;;^UTILITY(U,$J,358.3,44827,1,4,0)
+64 ;;=4^L49.7
+65 ;;^UTILITY(U,$J,358.3,44827,2)
+66 ;;=^5009197
+67 ;;^UTILITY(U,$J,358.3,44828,0)
+68 ;;=L49.8^^170^2237^24
+69 ;;^UTILITY(U,$J,358.3,44828,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,44828,1,3,0)
+72 ;;=3^Exfoliation d/t Erythematous Cond w/ 80-89% Body Surface
+73 ;;^UTILITY(U,$J,358.3,44828,1,4,0)
+74 ;;=4^L49.8
+75 ;;^UTILITY(U,$J,358.3,44828,2)
+76 ;;=^5009198
+77 ;;^UTILITY(U,$J,358.3,44829,0)
+78 ;;=L49.9^^170^2237^27
+79 ;;^UTILITY(U,$J,358.3,44829,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,44829,1,3,0)
+82 ;;=3^Exfoliation d/t Erythematous Cond w/ > 89% Body Surface
+83 ;;^UTILITY(U,$J,358.3,44829,1,4,0)
+84 ;;=4^L49.9
+85 ;;^UTILITY(U,$J,358.3,44829,2)
+86 ;;=^5009199
+87 ;;^UTILITY(U,$J,358.3,44830,0)
+88 ;;=Z65.5^^170^2237^28
+89 ;;^UTILITY(U,$J,358.3,44830,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,44830,1,3,0)
+92 ;;=3^Exposure to Disaster/War/Hostilities
+93 ;;^UTILITY(U,$J,358.3,44830,1,4,0)
+94 ;;=4^Z65.5
+95 ;;^UTILITY(U,$J,358.3,44830,2)
+96 ;;=^5063184
+97 ;;^UTILITY(U,$J,358.3,44831,0)
+98 ;;=Z77.22^^170^2237^29
+99 ;;^UTILITY(U,$J,358.3,44831,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,44831,1,3,0)
+102 ;;=3^Exposure to/Contact w/ Environmental Tobacco Smoke
+103 ;;^UTILITY(U,$J,358.3,44831,1,4,0)
+104 ;;=4^Z77.22
+105 ;;^UTILITY(U,$J,358.3,44831,2)
+106 ;;=^5063324
+107 ;;^UTILITY(U,$J,358.3,44832,0)
+108 ;;=L30.9^^170^2237^5
+109 ;;^UTILITY(U,$J,358.3,44832,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,44832,1,3,0)
+112 ;;=3^Eczema,Unspec
+113 ;;^UTILITY(U,$J,358.3,44832,1,4,0)
+114 ;;=4^L30.9
+115 ;;^UTILITY(U,$J,358.3,44832,2)
+116 ;;=^5009159
